ESH 2017 | Integrating midostaurin into FLT3 positive AML treatment
Miguel Sanz
• 5 Oct 2016
In the RATIFY clinical trial (NCT00651261), the FLT3 inhibitor midostaurin plus standard chemotherapy was shown to have an advantage over standard chemotherapy alone when treating AML patients who were positive for the FLT3 mutation. In this interview, Miguel Sanz, MD, of the University Hospital La Fe, Valencia, Spain, discusses how midostaurin use will start to become widespread in the near future in Spain, and touches upon current trials that may show it to have use in other clinical contexts as well. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
